Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Chief Scientific Officer | July 31, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date July 31, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 113,699 |
Reported balance
After 2026-07-31 transaction · row 1
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 875 · Balance 113,699 F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 2, 2023 22:11 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,183 | $13.78 | $30,081.74 |
DisclosureSEC source: 0001104659-23-009975 · tm235311-4_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,456 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:11 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009975 · tm235311-4_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,639 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:11 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,436 | $10.21 | $14,659.41 |
DisclosureSEC source: 0001104659-23-009975 · tm235311-4_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,473 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2022 through January 31, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2022. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:31 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 37,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009354 · tm235142-3_4seq1.xml · derivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,100 Underlying: Common Stock, par value $0.0001 · 37,100 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2023 Filed Feb 1, 2023 22:31 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 105,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001104659-23-009354 · tm235142-3_4seq1.xml · derivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock, par value $0.0001 · 105,000 shares Expires 2033-01-30 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 30, 2024 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 30, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 31, 2022 Filed Aug 3, 2022 20:06 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 732 | $6.86 | $5,021.52 |
DisclosureSEC source: 0001104659-22-085619 · tm2222488-2_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,037 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2022 through July 31, 2022. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 787 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · derivative · entry 9 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock, par value $0.0001 · 787 shares Expires 2029-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 10,182 | $12.00 | $122,184.00 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,305 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 05, 2022 Filed Jul 5, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 787 | $2.95 | $2,321.65 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 22,963 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · derivative · entry 8 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,037 Underlying: Common Stock, par value $0.0001 · 22,963 shares Expires 2029-03-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 4,019 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · derivative · entry 7 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock, par value $0.0001 · 4,019 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 26,982 | $12.00 | $323,784.00 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 22,963 | $2.95 | $67,740.85 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,682 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 4,019 | $2.60 | $10,449.40 |
DisclosureSEC source: 0001104659-22-077433 · tm2220386-1_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 5,462 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-22-076291 · tm2220183-1_4seq1.xml · derivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,769 Underlying: Common Stock, par value $0.0001 · 5,462 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 5,462 | $12.00 | $65,546.18 |
DisclosureSEC source: 0001104659-22-076291 · tm2220183-1_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.0050, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 5,462 | $2.60 | $14,201.20 |
DisclosureSEC source: 0001104659-22-076291 · tm2220183-1_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 11,769 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · derivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,231 Underlying: Common Stock, par value $0.0001 · 30,000 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 25,583 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · derivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,817 Underlying: Common Stock, par value $0.0001 · 61,400 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | SaleCommon Stock, par value $0.0001 | 37,352 | $12.00 | $448,253.88 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.0250, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 11,769 | $2.60 | $30,599.40 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 25,583 | $1.92 | $49,152.62 |
DisclosureSEC source: 0001104659-22-075361 · tm2219797-2_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:55 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 31,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · derivative · entry 7 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,100 Underlying: Common Stock, par value $0.0001 · 31,100 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F7 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 00:55 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 91,600 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · derivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,600 Underlying: Common Stock, par value $0.0001 · 91,600 shares Expires 2032-02-02 F6 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 2, 2023 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2023, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:55 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · derivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,498 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:55 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,183 | $7.98 | $17,420.34 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,700 F4 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 00:55 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2022 Filed Feb 4, 2022 00:55 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 2,106 | $6.86 | $14,447.16 |
DisclosureSEC source: 0001104659-22-011517 · tm225504-1_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,717 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2021 through January 31, 2022. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2022. Read SEC document |
| July 31, 2021 Filed Aug 6, 2021 23:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,750 | $7.71 | $13,491.63 |
DisclosureSEC source: 0001104659-21-101661 · tm2124283-1_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,611 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2021 through July 31, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2021. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 24,664 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-004756 · doc4.xml · derivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,664 Underlying: Common Stock, par value $0.0001 · 24,664 shares Expires not disclosed F4 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested and exercisable in substantially equal annual installments over the 4 years following February 2, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 90,000 | $0.00 Strike: $16.71 | $0.00 |
DisclosureSEC source: 0000899243-21-004756 · doc4.xml · derivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock, par value $0.0001 · 90,000 shares Expires 2031-02-01 F3 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on February 1, 2022 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 31, 2021 Filed Feb 4, 2021 00:00 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 467 | $12.14 | $5,669.38 |
DisclosureSEC source: 0000899243-21-004756 · doc4.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,861 F1 · kind: These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2020 through January 31, 2021. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2021. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 22:43 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 3,859 | $1.46 | $5,634.14 |
DisclosureSEC source: 0000899243-20-021207 · doc4.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,394 F1 · kind: These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2020 through July 31, 2020. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on February 1, 2020. Read SEC document |
| January 31, 2020 Filed Feb 5, 2020 01:15 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 3,698 | $1.46 | $5,399.08 |
DisclosureSEC source: 0000899243-20-002960 · doc4.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,535 F1 · kind: These shares were purchased due to participation by the reporting individual in the issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2019 through January 31, 2020. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on January 31, 2020. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 22:06 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 61,400 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0000899243-20-000286 · doc4.xml · derivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,400 Underlying: Common Stock, par value $0.0001 · 61,400 shares Expires 2030-01-02 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 2, 2021 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 2, 2021, subject to the reporting person's continued service through the applicable vesting date Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 21:46 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 38,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0000925421-19-000135 · edgar.xml · derivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock, par value $0.0001 · 38,000 shares Expires 2029-03-26 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:58 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 30,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001012975-19-000028 · edgar.xml · derivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock, par value $0.0001 · 30,000 shares Expires 2029-01-02 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on the first anniversary of the Grant Date and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following the one-year anniversary of the Grant Date, in each case, generally subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:23 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionStock Options (option to buy) · Derivative | 55,120 | $0.00 Strike: $0.08 | $0.00 |
DisclosureSEC source: 0001012975-18-000457 · edgar.xml · derivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 55,120 shares Expires 2022-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:23 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 50,016 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001012975-18-000457 · edgar.xml · derivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,016 Underlying: Common Stock, par value $0.0001 · 50,016 shares Expires 2028-05-21 F1 · derivative.exercise_date: Twenty-five percent of the option becomes vested and exercisable on March 1, 2019, and the aggregate unvested remaining portion will vest and become exercisable in equal monthly installments on the first day of each month over the 36-month period starting April 1, 2019. Read SEC document |
| May 21, 2018 Filed May 23, 2018 21:23 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 55,120 | $0.08 | $4,409.60 |
DisclosureSEC source: 0001012975-18-000457 · edgar.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 22, 2017 Filed Sep 26, 2017 22:37 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 50,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001012975-17-000721 · edgar.xml · derivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock, par value $0.0001 · 50,000 shares Expires 2027-09-22 F1 · derivative.exercise_date: On the first anniversary of the date of grant, 25% of the unvested portion of the option will become vested and exercisable, and the aggregate remaining unvested portion will vest and become exercisable in equal monthly installments over the 36-month period following such anniversary date. Read SEC document |
| June 06, 2017 Filed Feb 23, 2018 21:21 UTC | Altimmune, Inc. ALT · Entity 5349 | PurchaseCommon Stock, par value $0.0001 | 449 | $4.42 | $1,984.58 |
DisclosureSEC source: 0001012975-18-000229 · edgar.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by spouse of Reporting Person Disclosed balance after: 449 Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 11,235 | Not disclosed Strike: $13.38 | Not disclosed |
DisclosureSEC source: 0000899243-17-012361 · doc4.xml · derivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,235 Underlying: Common Stock, par value $0.0001 · 11,235 shares Expires 2026-04-07 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. F4 · derivative.exercise_date: The option is currently exercisable to purchase 2,809 shares of Common Stock. An additional 25% of the option will vest on each of 3/2/2018, 3/2/2019, and 3/2/2020. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 8,956 | Not disclosed Strike: $2.59 | Not disclosed |
DisclosureSEC source: 0000899243-17-012361 · doc4.xml · derivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,956 Underlying: Common Stock, par value $0.0001 · 8,956 shares Expires 2024-12-02 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. F3 · derivative.exercise_date: The option is currently exercisable to purchase 4,477 shares of Common Stock. An additional 25% of the option will vest on each of 12/3/2017 and 12/3/2018. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 8,956 | Not disclosed Strike: $0.59 | Not disclosed |
DisclosureSEC source: 0000899243-17-012361 · doc4.xml · derivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,956 Underlying: Common Stock, par value $0.0001 · 8,956 shares Expires 2023-12-04 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. F2 · derivative.exercise_date: The option is currently exercisable to purchase 6,716 shares of the Issuer's common stock, par value $0.0001 ("Common Stock"). The remaining portion of the option will vest on 12/4/2017. Read SEC document |
| May 04, 2017 Filed May 9, 2017 00:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantStock Option (option to buy) · Derivative | 55,120 | Not disclosed Strike: $0.08 | Not disclosed |
DisclosureSEC source: 0000899243-17-012361 · doc4.xml · derivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,120 Underlying: Common Stock, par value $0.0001 · 55,120 shares Expires 2022-12-05 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.